Arvinas to Participate in Upcoming Investor Conferences
June 05, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., June 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 08, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn. and NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated data related to vepdegestrant...
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 05, 2023 07:00 ET
|
Arvinas Inc.
–Multiple vepdegestrant (ARV-471) studies enrolling globally, including Phase 1, 2, and 3 studies– – Preliminary data from the Phase 1b combination trial of vepdegestrant + palbociclib suggests...
Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference
May 03, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., May 03, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at Stifel Targeted Oncology Day
April 21, 2023 16:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., April 21, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Participate in Upcoming Investor Conferences
February 27, 2023 16:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 23, 2023 07:00 ET
|
Arvinas Inc.
– Initiated multiple trials with ARV-471, including a 2L+ Phase 3 trial for patients with metastatic breast cancer – – Presented Phase 2 monotherapy expansion data from the VERITAC trial for the...
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
February 09, 2023 09:05 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will...
Arvinas to Participate in Upcoming Investor Conferences
February 06, 2023 16:30 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...